🩺 CorDx Health Test: Microalbuminuria (MAU) – Early Detection for Chronic Disease Management CorDx’s Health Test portfolio focuses on providing crucial indicators for managing chronic, high-burden conditions, exemplified by our Microalbuminuria (MAU) Test. This diagnostic tool plays a vital role in the early identification and monitoring of kidney and cardiovascular risk, particularly in high-risk global populations.
🔬 The Science of Renal Risk Assessment
The Microalbuminuria (MAU) Test is a highly sensitive Lateral Flow Immunoassay (LFIA) designed for rapid detection of slightly elevated levels of albumin protein in a Urine sample.
Clinical Significance: MAU is a key marker of endothelial dysfunction and is recognised globally as an early indicator of kidney damage, especially in patients with diabetes and hypertension. Early detection is crucial, as the presence of MAU strongly predicts the progression to overt kidney disease (nephropathy) and an increased risk of severe cardiovascular events (like heart attack and stroke).
Precision and Thresholds: Our test is calibrated to a detection limit of 20μg/ml, which is an internationally recognised clinical threshold for identifying pathologically increased albumin excretion, allowing for sensitive screening outside of traditional lab settings.
User-Friendly Format: Provided in a Cassette format, the test is simple to perform and interpret, making it an ideal point-ofcare or decentralised testing solution for mass screening and routine patient follow-up.
🏭 CorDx’s Global Commitment: Accessibility in Chronic Care
CorDx’s strategy leverages its vertically integrated supply chain to ensure this essential health test is available and affordable worldwide, addressing the rising global incidence of chronic diseases:
Manufacturing Efficiency: Controlling the entire production process reduces costs and allows us to provide a high-quality MAU test solution that can be utilised affordably in public health screening programs, especially in regions with limited laboratory infrastructure.
Scalable Distribution: Our global logistics network ensures that healthcare providers treating patients with diabetes, hypertension, or cardiovascular disease have reliable access to the necessary supply of MAU tests for annual or routine monitoring, fulfilling guidelines from bodies like the American Diabetes Association and European Society of Cardiology.
✅ Validated for Trust: CE Compliance
The CorDx Microalbuminuria Test carries the CE Mark, confirming its adherence to the European Union’s rigorous standards for safety, performance, and quality for In Vitro Diagnostic medical devices. This regulatory validation enables the test's deployment across the EU and other global markets that recognise the CE certification, reinforcing its status as a clinically trusted tool in proactive health management.
By providing a precise, accessible, and compliant MAU test, CorDx empowers clinicians to detect the early signs of vascular and renal damage, facilitating timely intervention that can slow disease progression and significantly improve longterm patient outcomes globally.